In last trading session, Cullinan Therapeutics Inc (NASDAQ:CGEM) saw 0.63 million shares changing hands with its beta currently measuring -0.11. Company’s recent per share price level of $16.71 trading at -$0.2 or -1.18% at ring of the bell on the day assigns it a market valuation of $968.85M. That closing price of CGEM’s stock is at a discount of -80.67% from its 52-week high price of $30.19 and is indicating a premium of 54.28% from its 52-week low price of $7.64. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.74 million shares which gives us an average trading volume of 824.42K if we extend that period to 3-months.
For Cullinan Therapeutics Inc (CGEM), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.78 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cullinan Therapeutics Inc (NASDAQ:CGEM) trade information
Upright in the red during last session for losing -1.18%, in the last five days CGEM remained trading in the red while hitting it’s week-highest on Friday, 08/16/24 when the stock touched $16.71 price level, adding 2.28% to its value on the day. Cullinan Therapeutics Inc’s shares saw a change of 63.98% in year-to-date performance and have moved -0.36% in past 5-day. Cullinan Therapeutics Inc (NASDAQ:CGEM) showed a performance of -9.14% in past 30-days. Number of shares sold short was 8.36 million shares which calculate 11.74 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 30 to the stock, which implies a rise of 44.3% to its current value. Analysts have been projecting 28 as a low price target for the stock while placing it at a high target of 38. It follows that stock’s current price would drop -67.56% in reaching the projected high whereas dropping to the targeted low would mean a loss of -67.56% for stock’s current value.
Cullinan Therapeutics Inc (CGEM) estimates and forecasts
Statistics highlight that Cullinan Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -9.33% of value to its shares in past 6 months, showing an annual growth rate of 13.28% while that of industry is 17.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -62.42% during past 5 years.
Cullinan Therapeutics Inc (NASDAQ:CGEM)’s Major holders
Insiders are in possession of 4.51% of company’s total shares while institution are holding 116.62 percent of that, with stock having share float percentage of 122.14%. Investors also watch the number of corporate investors in a company very closely, which is 116.62% institutions for Cullinan Therapeutics Inc that are currently holding shares of the company. BIOIMPACT CAPITAL LLC is the top institutional holder at CGEM for having 7.65 million shares of worth $130.33 million. And as of 2024-03-31, it was holding 17.8723 of the company’s outstanding shares.
The second largest institutional holder is BVF INC/IL, which was holding about 3.2 million shares on 2024-03-31. The number of shares represents firm’s hold over 7.47 of outstanding shares, having a total worth of $54.47 million.
On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Jun 30, 2024 , the former fund manager was holding 1.05 shares of worth $17.56 million or 1.81% of the total outstanding shares. The later fund manager was in possession of 944.49 shares on Jun 30, 2024 , making its stake of worth around $15.78 million in the company or a holder of 1.63% of company’s stock.
